ADARx Pharmaceuticals, Inc.
NASDAQ:ADRXBiotechnology
+$0.13 today
- Market cap
- $1.42B
- Beta
- 0.00
Volume 0.65M
Average 1.06M
ADRX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Research & Development history
Currency unavailable · from the income statement
No Research & Development data reported for this period type.
Research & Development vs competitors
How ADRX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $189.6M USD | +13.6% | +16.4% | 264.1% | |
| LTM Mar 2026 | $154.18M USD | -2.5% | +22.8% | 3822.0% | |
| LTM Mar 2026 | $144.07M USD | +45.7% | +21.0% | 449.1% | |
| LTM Mar 2026 | $128.82M USD | +9.2% | +14.8% | 161.5% | |
| LTM Mar 2026 | $98.25M USD | -44.3% | -8.8% | 216.6% | |
| LTM Mar 2026 | $61.84M USD | — | +24.0% | 6710.8% | |
| FY2025 | $53.76M USD | — | — | 288.7% | |
| LTM Mar 2026 | €44.34M EUR | +12.6% | -7.1% | 329.9% | |
| LTM Mar 2026 | $19.2M USD | +1.2% | +17.6% | — | |
ADRXADARx Pharmaceuticals, Inc. | — | — | — | — | — |
| Peer median (excluding ADRX) | — | +9.2% | +17.0% | 309.3% | |
Competitors are the stored peer set for ADRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
ADARx Pharmaceuticals, Inc.
NASDAQ:ADRX
Intrinsic Alpha fair value
Locked
Current Price
$12.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.